ID   F16P1_PIG               Reviewed;         338 AA.
AC   P00636;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   24-JUN-2015, entry version 140.
DE   RecName: Full=Fructose-1,6-bisphosphatase 1;
DE            Short=FBPase 1;
DE            EC=3.1.3.11;
DE   AltName: Full=D-fructose-1,6-bisphosphate 1-phosphohydrolase 1;
DE   AltName: Full=Liver FBPase;
GN   Name=FBP1; Synonyms=FBP;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=1313579; DOI=10.1073/pnas.89.7.3080;
RA   Williams M.K., Kantrowitz E.R.;
RT   "Isolation and sequence analysis of the cDNA for pig kidney fructose
RT   1,6-bisphosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3080-3082(1992).
RN   [2]
RP   PROTEIN SEQUENCE OF 2-336, ACETYLATION AT THR-2, AND PHOSPHORYLATION
RP   AT SER-208.
RC   TISSUE=Kidney cortex;
RX   PubMed=6296821; DOI=10.1073/pnas.79.23.7161;
RA   Marcus F., Edelstein I., Reardon I., Heinrikson R.L.;
RT   "Complete amino acid sequence of pig kidney fructose-1,6-
RT   bisphosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:7161-7165(1982).
RN   [3]
RP   PROTEIN SEQUENCE OF 2-24 AND 44-61, AND ACETYLATION AT THR-2.
RC   TISSUE=Kidney;
RX   PubMed=6291465; DOI=10.1016/0003-9861(82)90547-1;
RA   McGregor J.S., Hannappel E., Xu G.-J., Pontremoli S., Horecker B.L.;
RT   "Conservation of primary structure at the proteinase-sensitive site of
RT   fructose 1,6-bisphosphatases.";
RL   Arch. Biochem. Biophys. 217:652-664(1982).
RN   [4]
RP   SUBSTRATE-BINDING SITE, LIGANDS, AND REVIEW.
RX   PubMed=6277165;
RA   Benkovic S.J., Demaine M.M.;
RT   "Mechanism of action of fructose 1,6-bisphosphatase.";
RL   Adv. Enzymol. Relat. Areas Mol. Biol. 53:45-82(1982).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH
RP   FRUCTOSE-2,6-BISPHOSPHATE, AND SEQUENCE REVISION.
RX   PubMed=2157849; DOI=10.1016/0022-2836(90)90329-K;
RA   Ke H.M., Thorpe C.M., Seaton B.A., Lipscomb W.N., Marcus F.;
RT   "Structure refinement of fructose-1,6-bisphosphatase and its fructose
RT   2,6-bisphosphate complex at 2.8-A resolution.";
RL   J. Mol. Biol. 212:513-539(1990).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH
RP   FRUCTOSE-6-PHOSPHATE; AMP AND MAGNESIUM, ENZYME REGULATION, AND
RP   SUBUNIT.
RX   PubMed=2164670; DOI=10.1073/pnas.87.14.5243;
RA   Ke H.M., Zhang Y.P., Lipscomb W.N.;
RT   "Crystal structure of fructose-1,6-bisphosphatase complexed with
RT   fructose 6-phosphate, AMP, and magnesium.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5243-5247(1990).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEX WITH
RP   FRUCTOSE-6-PHOSPHATE.
RX   PubMed=1849642; DOI=10.1073/pnas.88.8.2989;
RA   Ke H.M., Zhang Y.P., Liang J.-Y., Lipscomb W.N.;
RT   "Crystal structure of the neutral form of fructose-1,6-bisphosphatase
RT   complexed with the product fructose 6-phosphate at 2.1-A resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:2989-2993(1991).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH
RP   FRUCTOSE-2,6-BISPHOSPHATE.
RX   PubMed=1312721; DOI=10.1073/pnas.89.6.2404;
RA   Liang J.-Y., Huang S., Zhang Y.P., Ke H.M., Lipscomb W.N.;
RT   "Crystal structure of the neutral form of fructose 1,6-bisphosphatase
RT   complexed with regulatory inhibitor fructose 2,6-bisphosphate at 2.6-A
RT   resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:2404-2408(1992).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) IN COMPLEX WITH ZINC IONS,
RP   COFACTOR, AND ENZYME REGULATION.
RX   PubMed=9708979; DOI=10.1021/bi981112u;
RA   Choe J.-Y., Poland B.W., Fromm H.J., Honzatko R.B.;
RT   "Role of a dynamic loop in cation activation and allosteric regulation
RT   of recombinant porcine fructose-1,6-bisphosphatase.";
RL   Biochemistry 37:11441-11450(1998).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) IN COMPLEXES WITH
RP   FRUCTOSE-6-PHOSPHATE; PHOSPHATE; AMP; MAGNESIUM AND ZINC IONS,
RP   SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=10913263; DOI=10.1021/bi000574g;
RA   Choe J.-Y., Fromm H.J., Honzatko R.B.;
RT   "Crystal structures of fructose 1,6-bisphosphatase: mechanism of
RT   catalysis and allosteric inhibition revealed in product complexes.";
RL   Biochemistry 39:8565-8574(2000).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) IN COMPLEXES WITH MAGNESIUM
RP   IONS; FRUCTOSE-6-PHOSPHATE AND PHOSPHATE, COFACTOR, AND ENZYME
RP   MECHANISM.
RX   PubMed=12595528; DOI=10.1074/jbc.M212395200;
RA   Choe J.-Y., Iancu C.V., Fromm H.J., Honzatko R.B.;
RT   "Metaphosphate in the active site of fructose-1,6-bisphosphatase.";
RL   J. Biol. Chem. 278:16015-16020(2003).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH THE SYNTHETIC
RP   INHIBITOR OC252; FRUCTOSE-6-PHOSPHATE; PHOSPHATE AND DIVALENT METAL
RP   CATIONS, COFACTOR, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=14530289; DOI=10.1074/jbc.M308396200;
RA   Choe J.-Y., Nelson S.W., Arienti K.L., Axe F.U., Collins T.L.,
RA   Jones T.K., Kimmich R.D.A., Newman M.J., Norvell K., Ripka W.C.,
RA   Romano S.J., Short K.M., Slee D.H., Fromm H.J., Honzatko R.B.;
RT   "Inhibition of fructose-1,6-bisphosphatase by a new class of
RT   allosteric effectors.";
RL   J. Biol. Chem. 278:51176-51183(2003).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF MUTANT LEU-55 IN COMPLEXES
RP   WITH AMP; FRUCTORSE-6-PHOSPHAT; PHOSPHATE AND MAGNESIUM IONS, SUBUNIT,
RP   COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.
RX   PubMed=15767255; DOI=10.1074/jbc.M501011200;
RA   Iancu C.V., Mukund S., Fromm H.J., Honzatko R.B.;
RT   "R-state AMP complex reveals initial steps of the quaternary
RT   transition of fructose-1,6-bisphosphatase.";
RL   J. Biol. Chem. 280:19737-19745(2005).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) IN COMPLEXES WITH MAGNESIUM IONS
RP   AND FRUCTOSE-2,6-DIPHOSPHATE, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=17933867; DOI=10.1074/jbc.M707302200;
RA   Hines J.K., Chen X., Nix J.C., Fromm H.J., Honzatko R.B.;
RT   "Structures of mammalian and bacterial fructose-1,6-bisphosphatase
RT   reveal the basis for synergism in AMP/fructose 2,6-bisphosphate
RT   inhibition.";
RL   J. Biol. Chem. 282:36121-36131(2007).
CC   -!- FUNCTION: Catalyzes the hydrolysis of fructose 1,6-bisphosphate to
CC       fructose 6-phosphate in the presence of divalent cations, acting
CC       as a rate-limiting enzyme in gluconeogenesis. Plays a role in
CC       regulating glucose sensing and insulin secretion of pancreatic
CC       beta-cells. Appears to modulate glycerol gluconeogenesis in liver.
CC       Important regulator of appetite and adiposity; increased
CC       expression of the protein in liver after nutrient excess increases
CC       circulating satiety hormones and reduces appetite-stimulating
CC       neuropeptides and thus seems to provide a feedback mechanism to
CC       limit weight gain (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: D-fructose 1,6-bisphosphate + H(2)O = D-
CC       fructose 6-phosphate + phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12595528,
CC         ECO:0000269|PubMed:14530289, ECO:0000269|PubMed:15767255,
CC         ECO:0000269|PubMed:9708979};
CC       Note=Binds 3 Mg(2+) ions per subunit.
CC       {ECO:0000269|PubMed:12595528, ECO:0000269|PubMed:14530289,
CC       ECO:0000269|PubMed:15767255, ECO:0000269|PubMed:9708979};
CC   -!- ENZYME REGULATION: Subject to complex allosteric regulation. The
CC       enzyme can assume an active R-state, or an inactive T-state.
CC       Intermediate conformations may exist. AMP acts as allosteric
CC       inhibitor. AMP binding affects the turnover of bound substrate and
CC       not the affinity for substrate. Fructose 2,6-bisphosphate acts as
CC       competitive inhibitor. Fructose 2,6-bisphosphate and AMP have
CC       synergistic effects. {ECO:0000269|PubMed:10913263,
CC       ECO:0000269|PubMed:14530289, ECO:0000269|PubMed:15767255,
CC       ECO:0000269|PubMed:17933867, ECO:0000269|PubMed:2164670,
CC       ECO:0000269|PubMed:9708979}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.2 uM for fructose-1,6-diphosphate
CC         {ECO:0000269|PubMed:15767255};
CC   -!- PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:10913263,
CC       ECO:0000269|PubMed:1312721, ECO:0000269|PubMed:14530289,
CC       ECO:0000269|PubMed:15767255, ECO:0000269|PubMed:17933867,
CC       ECO:0000269|PubMed:1849642, ECO:0000269|PubMed:2157849,
CC       ECO:0000269|PubMed:2164670, ECO:0000269|PubMed:9708979}.
CC   -!- MISCELLANEOUS: The molecule has a highly reactive cysteine residue
CC       (Cys-117 or Cys-129), which tends to form mixed disulfides (e.g.
CC       with homocystine) but is not essential for enzyme activity.
CC   -!- SIMILARITY: Belongs to the FBPase class 1 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M86347; AAA31035.1; -; mRNA.
DR   PIR; S37696; PAPGF.
DR   RefSeq; NP_999144.1; NM_213979.1.
DR   UniGene; Ssc.5127; -.
DR   PDB; 1CNQ; X-ray; 2.27 A; A=2-338.
DR   PDB; 1EYI; X-ray; 2.32 A; A=2-338.
DR   PDB; 1EYJ; X-ray; 2.28 A; A/B=2-338.
DR   PDB; 1EYK; X-ray; 2.23 A; A/B=2-338.
DR   PDB; 1FBC; X-ray; 2.60 A; A/B=2-336.
DR   PDB; 1FBD; X-ray; 2.90 A; A/B=2-336.
DR   PDB; 1FBE; X-ray; 3.00 A; A/B=2-336.
DR   PDB; 1FBF; X-ray; 2.70 A; A/B=2-336.
DR   PDB; 1FBG; X-ray; 3.00 A; A/B=2-336.
DR   PDB; 1FBH; X-ray; 2.50 A; A/B=2-336.
DR   PDB; 1FBP; X-ray; 2.50 A; A/B=2-336.
DR   PDB; 1FJ6; X-ray; 2.50 A; A=2-338.
DR   PDB; 1FJ9; X-ray; 2.50 A; A/B=2-338.
DR   PDB; 1FPB; X-ray; 2.60 A; A/B=2-336.
DR   PDB; 1FPD; X-ray; 2.10 A; A/B=2-336.
DR   PDB; 1FPE; X-ray; 2.20 A; A/B=2-336.
DR   PDB; 1FPF; X-ray; 2.10 A; A/B=2-336.
DR   PDB; 1FPG; X-ray; 2.30 A; A/B=2-336.
DR   PDB; 1FPI; X-ray; 2.30 A; A/B=2-336.
DR   PDB; 1FPJ; X-ray; 2.20 A; A/B=2-336.
DR   PDB; 1FPK; X-ray; 3.00 A; A/B=2-336.
DR   PDB; 1FPL; X-ray; 2.30 A; A/B=2-336.
DR   PDB; 1FRP; X-ray; 2.00 A; A/B=2-336.
DR   PDB; 1FSA; X-ray; 2.30 A; A/B=2-338.
DR   PDB; 1KZ8; X-ray; 2.00 A; A/F=2-338.
DR   PDB; 1LEV; X-ray; 2.15 A; A/F=2-338.
DR   PDB; 1NUW; X-ray; 1.30 A; A=2-338.
DR   PDB; 1NUX; X-ray; 1.60 A; A=2-338.
DR   PDB; 1NUY; X-ray; 1.30 A; A=2-338.
DR   PDB; 1NUZ; X-ray; 1.90 A; A=2-338.
DR   PDB; 1NV0; X-ray; 1.80 A; A=2-338.
DR   PDB; 1NV1; X-ray; 1.90 A; A=2-338.
DR   PDB; 1NV2; X-ray; 2.10 A; A=2-338.
DR   PDB; 1NV3; X-ray; 2.00 A; A=2-338.
DR   PDB; 1NV4; X-ray; 1.90 A; A=2-338.
DR   PDB; 1NV5; X-ray; 1.90 A; A=2-338.
DR   PDB; 1NV6; X-ray; 2.15 A; A=2-338.
DR   PDB; 1NV7; X-ray; 2.15 A; A/B=2-338.
DR   PDB; 1Q9D; X-ray; 2.35 A; A/B=2-338.
DR   PDB; 1RDX; X-ray; 2.75 A; A/B=2-338.
DR   PDB; 1RDY; X-ray; 2.20 A; A/B=2-338.
DR   PDB; 1RDZ; X-ray; 2.05 A; A/B=2-338.
DR   PDB; 1YXI; X-ray; 2.00 A; A=2-338.
DR   PDB; 1YYZ; X-ray; 1.85 A; A=2-338.
DR   PDB; 1YZ0; X-ray; 2.07 A; A/B=2-338.
DR   PDB; 2F3B; X-ray; 1.80 A; A=1-338.
DR   PDB; 2F3D; X-ray; 1.83 A; A=1-338.
DR   PDB; 2FBP; X-ray; 2.80 A; A/B=2-336.
DR   PDB; 2QVU; X-ray; 1.50 A; A/B=2-338.
DR   PDB; 2QVV; X-ray; 2.03 A; A/B=2-338.
DR   PDB; 3FBP; X-ray; 2.80 A; A/B=2-336.
DR   PDB; 4FBP; X-ray; 2.50 A; A/B/C/D=2-336.
DR   PDB; 4GBV; X-ray; 2.90 A; A=2-336.
DR   PDB; 4GBW; X-ray; 2.00 A; A=2-336.
DR   PDB; 4GWS; X-ray; 2.75 A; A/B=2-338.
DR   PDB; 4GWU; X-ray; 3.00 A; A=2-338.
DR   PDB; 4GWW; X-ray; 3.20 A; A=2-338.
DR   PDB; 4GWX; X-ray; 2.35 A; A=2-338.
DR   PDB; 4GWY; X-ray; 3.00 A; A=2-338.
DR   PDB; 4GWZ; X-ray; 2.60 A; A/B=2-338.
DR   PDB; 4GX3; X-ray; 2.25 A; A/B=2-338.
DR   PDB; 4GX4; X-ray; 2.50 A; A/B=2-338.
DR   PDB; 4GX6; X-ray; 2.50 A; A/B=2-338.
DR   PDB; 4H45; X-ray; 3.10 A; A=2-338.
DR   PDB; 4H46; X-ray; 2.50 A; A=2-338.
DR   PDB; 4KXP; X-ray; 2.70 A; A/B=1-338.
DR   PDB; 5FBP; X-ray; 2.10 A; A/B=2-336.
DR   PDBsum; 1CNQ; -.
DR   PDBsum; 1EYI; -.
DR   PDBsum; 1EYJ; -.
DR   PDBsum; 1EYK; -.
DR   PDBsum; 1FBC; -.
DR   PDBsum; 1FBD; -.
DR   PDBsum; 1FBE; -.
DR   PDBsum; 1FBF; -.
DR   PDBsum; 1FBG; -.
DR   PDBsum; 1FBH; -.
DR   PDBsum; 1FBP; -.
DR   PDBsum; 1FJ6; -.
DR   PDBsum; 1FJ9; -.
DR   PDBsum; 1FPB; -.
DR   PDBsum; 1FPD; -.
DR   PDBsum; 1FPE; -.
DR   PDBsum; 1FPF; -.
DR   PDBsum; 1FPG; -.
DR   PDBsum; 1FPI; -.
DR   PDBsum; 1FPJ; -.
DR   PDBsum; 1FPK; -.
DR   PDBsum; 1FPL; -.
DR   PDBsum; 1FRP; -.
DR   PDBsum; 1FSA; -.
DR   PDBsum; 1KZ8; -.
DR   PDBsum; 1LEV; -.
DR   PDBsum; 1NUW; -.
DR   PDBsum; 1NUX; -.
DR   PDBsum; 1NUY; -.
DR   PDBsum; 1NUZ; -.
DR   PDBsum; 1NV0; -.
DR   PDBsum; 1NV1; -.
DR   PDBsum; 1NV2; -.
DR   PDBsum; 1NV3; -.
DR   PDBsum; 1NV4; -.
DR   PDBsum; 1NV5; -.
DR   PDBsum; 1NV6; -.
DR   PDBsum; 1NV7; -.
DR   PDBsum; 1Q9D; -.
DR   PDBsum; 1RDX; -.
DR   PDBsum; 1RDY; -.
DR   PDBsum; 1RDZ; -.
DR   PDBsum; 1YXI; -.
DR   PDBsum; 1YYZ; -.
DR   PDBsum; 1YZ0; -.
DR   PDBsum; 2F3B; -.
DR   PDBsum; 2F3D; -.
DR   PDBsum; 2FBP; -.
DR   PDBsum; 2QVU; -.
DR   PDBsum; 2QVV; -.
DR   PDBsum; 3FBP; -.
DR   PDBsum; 4FBP; -.
DR   PDBsum; 4GBV; -.
DR   PDBsum; 4GBW; -.
DR   PDBsum; 4GWS; -.
DR   PDBsum; 4GWU; -.
DR   PDBsum; 4GWW; -.
DR   PDBsum; 4GWX; -.
DR   PDBsum; 4GWY; -.
DR   PDBsum; 4GWZ; -.
DR   PDBsum; 4GX3; -.
DR   PDBsum; 4GX4; -.
DR   PDBsum; 4GX6; -.
DR   PDBsum; 4H45; -.
DR   PDBsum; 4H46; -.
DR   PDBsum; 4KXP; -.
DR   PDBsum; 5FBP; -.
DR   ProteinModelPortal; P00636; -.
DR   SMR; P00636; 7-338.
DR   STRING; 9823.ENSSSCP00000011671; -.
DR   BindingDB; P00636; -.
DR   ChEMBL; CHEMBL2263; -.
DR   PaxDb; P00636; -.
DR   PRIDE; P00636; -.
DR   GeneID; 397038; -.
DR   KEGG; ssc:397038; -.
DR   CTD; 2203; -.
DR   eggNOG; COG0158; -.
DR   HOGENOM; HOG000191265; -.
DR   HOVERGEN; HBG005627; -.
DR   InParanoid; P00636; -.
DR   KO; K03841; -.
DR   BRENDA; 3.1.3.11; 6170.
DR   SABIO-RK; P00636; -.
DR   UniPathway; UPA00138; -.
DR   EvolutionaryTrace; P00636; -.
DR   PRO; PR:P00636; -.
DR   Proteomes; UP000008227; Unplaced.
DR   Genevisible; P00636; SS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0016208; F:AMP binding; ISS:UniProtKB.
DR   GO; GO:0042132; F:fructose 1,6-bisphosphate 1-phosphatase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; ISS:UniProtKB.
DR   GO; GO:0048029; F:monosaccharide binding; ISS:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; ISS:UniProtKB.
DR   GO; GO:0071286; P:cellular response to magnesium ion; ISS:UniProtKB.
DR   GO; GO:0016311; P:dephosphorylation; ISS:UniProtKB.
DR   GO; GO:0006002; P:fructose 6-phosphate metabolic process; ISS:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0046580; P:negative regulation of Ras protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; ISS:UniProtKB.
DR   HAMAP; MF_01855; FBPase_class1; 1.
DR   InterPro; IPR000146; FBPase_class-1/SBPase.
DR   InterPro; IPR028343; FBPtase.
DR   InterPro; IPR020548; Fructose_bisphosphatase_AS.
DR   PANTHER; PTHR11556; PTHR11556; 1.
DR   Pfam; PF00316; FBPase; 1.
DR   PIRSF; PIRSF500210; FBPtase; 1.
DR   PIRSF; PIRSF000904; FBPtase_SBPase; 1.
DR   PRINTS; PR00115; F16BPHPHTASE.
DR   PROSITE; PS00124; FBPASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Carbohydrate metabolism;
KW   Complete proteome; Direct protein sequencing; Gluconeogenesis;
KW   Hydrolase; Magnesium; Metal-binding; Phosphoprotein;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:6291465,
FT                                ECO:0000269|PubMed:6296821}.
FT   CHAIN         2    338       Fructose-1,6-bisphosphatase 1.
FT                                /FTId=PRO_0000200500.
FT   NP_BIND      18     22       AMP. {ECO:0000269|PubMed:2164670}.
FT   NP_BIND      28     32       AMP. {ECO:0000269|PubMed:2164670}.
FT   NP_BIND     113    114       AMP. {ECO:0000269|PubMed:2164670}.
FT   REGION      122    125       Substrate binding.
FT   REGION      213    216       Substrate binding.
FT   REGION      244    249       Substrate binding.
FT   REGION      275    277       Substrate binding.
FT   METAL        69     69       Magnesium 1.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL        98     98       Magnesium 1.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL        98     98       Magnesium 2.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL       119    119       Magnesium 2.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL       119    119       Magnesium 3.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL       121    121       Magnesium 2; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL       122    122       Magnesium 3.
FT                                {ECO:0000269|PubMed:2164670}.
FT   METAL       281    281       Magnesium 3.
FT                                {ECO:0000269|PubMed:2164670}.
FT   BINDING     141    141       AMP. {ECO:0000269|PubMed:2164670}.
FT   BINDING     265    265       Substrate.
FT   MOD_RES       2      2       N-acetylthreonine.
FT                                {ECO:0000269|PubMed:6291465,
FT                                ECO:0000269|PubMed:6296821}.
FT   MOD_RES     151    151       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9QXD6}.
FT   MOD_RES     208    208       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:6296821}.
FT   MOD_RES     216    216       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9QXD6}.
FT   MOD_RES     265    265       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P09467}.
FT   MUTAGEN      55     55       A->L: Destabilizes the inactive T-state
FT                                and promotes transition to the R-state.
FT   CONFLICT      2      2       T -> A (in Ref. 3; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT      4      4       Q -> E (in Ref. 3; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     21     21       E -> Q (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     97     97       S -> T (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    157    157       G -> E (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    200    200       D -> N (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       Q -> E (in Ref. 2; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        14     24       {ECO:0000244|PDB:1NUW}.
FT   HELIX        30     50       {ECO:0000244|PDB:1NUW}.
FT   TURN         51     56       {ECO:0000244|PDB:1NUW}.
FT   STRAND       59     64       {ECO:0000244|PDB:1NUW}.
FT   STRAND       66     68       {ECO:0000244|PDB:1NV1}.
FT   STRAND       70     72       {ECO:0000244|PDB:1NUW}.
FT   HELIX        73     88       {ECO:0000244|PDB:1NUW}.
FT   STRAND       92     97       {ECO:0000244|PDB:1NUW}.
FT   STRAND      101    105       {ECO:0000244|PDB:1FSA}.
FT   HELIX       108    110       {ECO:0000244|PDB:1NUW}.
FT   STRAND      111    122       {ECO:0000244|PDB:1NUW}.
FT   HELIX       124    126       {ECO:0000244|PDB:1NUW}.
FT   TURN        127    130       {ECO:0000244|PDB:1NUW}.
FT   STRAND      133    141       {ECO:0000244|PDB:1NUW}.
FT   STRAND      144    146       {ECO:0000244|PDB:2QVU}.
FT   STRAND      147    149       {ECO:0000244|PDB:3FBP}.
FT   HELIX       150    153       {ECO:0000244|PDB:1NUW}.
FT   HELIX       157    159       {ECO:0000244|PDB:1NUW}.
FT   STRAND      161    178       {ECO:0000244|PDB:1NUW}.
FT   STRAND      181    188       {ECO:0000244|PDB:1NUW}.
FT   TURN        189    192       {ECO:0000244|PDB:1NUW}.
FT   STRAND      193    198       {ECO:0000244|PDB:1NUW}.
FT   STRAND      208    211       {ECO:0000244|PDB:1NUW}.
FT   HELIX       214    219       {ECO:0000244|PDB:1NUW}.
FT   HELIX       222    232       {ECO:0000244|PDB:1NUW}.
FT   STRAND      235    237       {ECO:0000244|PDB:1LEV}.
FT   STRAND      242    245       {ECO:0000244|PDB:1FBC}.
FT   HELIX       249    259       {ECO:0000244|PDB:1NUW}.
FT   STRAND      262    265       {ECO:0000244|PDB:1NUW}.
FT   STRAND      268    270       {ECO:0000244|PDB:1FPD}.
FT   TURN        271    273       {ECO:0000244|PDB:1FBP}.
FT   STRAND      275    277       {ECO:0000244|PDB:1NUW}.
FT   TURN        278    281       {ECO:0000244|PDB:1NUW}.
FT   HELIX       282    291       {ECO:0000244|PDB:1NUW}.
FT   STRAND      295    297       {ECO:0000244|PDB:1NUW}.
FT   STRAND      299    302       {ECO:0000244|PDB:1NUW}.
FT   HELIX       303    305       {ECO:0000244|PDB:1NUW}.
FT   STRAND      309    312       {ECO:0000244|PDB:1FBP}.
FT   STRAND      317    320       {ECO:0000244|PDB:1NUW}.
FT   HELIX       322    334       {ECO:0000244|PDB:1NUW}.
SQ   SEQUENCE   338 AA;  36779 MW;  610BF8D3C6D320F6 CRC64;
     MTDQAAFDTN IVTLTRFVME EGRKARGTGE MTQLLNSLCT AVKAISTAVR KAGIAHLYGI
     AGSTNVTGDQ VKKLDVLSND LVINVLKSSF ATCVLVSEED KNAIIVEPEK RGKYVVCFDP
     LDGSSNIDCL VSIGTIFGIY RKNSTDEPSE KDALQPGRNL VAAGYALYGS ATMLVLAMVN
     GVNCFMLDPA IGEFILVDRD VKIKKKGSIY SINEGYAKEF DPAITEYIQR KKFPPDNSAP
     YGARYVGSMV ADVHRTLVYG GIFMYPANKK SPKGKLRLLY ECNPMAYVME KAGGLATTGK
     EAVLDIVPTD IHQRAPIILG SPEDVTELLE IYQKHAAK
//
